Objective Ocular diseases are not only relevant social, sanitary and economic issues, but also a growing market opportunity in an increasingly ageing population. Ophthalmology is a health care area where the availability of easy to use point of care (PoC) medical devices based on biomarkers is fundamental for improving patient vision care, reducing number and frequency of sick leave and disability due to visual problems and for getting a significant reduction of overcrowding of ophthalmology units at health systems. The use of medical devices able to detect and measure biomarkers in human samples in a fast and non-invasive method will allow the easy introduction of these systems at the doctor’s office, thus enabling diagnosis of diseases in an objective manner and accurately monitoring of treatments effectiveness to be introduced into the standard clinical protocols.The present project is aimed to the clinical validation and market introduction of a device previously developed for ocular surface diseases (OSDs), named Tear Monitor and focused on diagnosis and monitoring of the Dry Eye and inflammation by measuring biomarkers in tears. For this purpose, two European SMEs specialised on ophthalmology establish a collaborative partnership to joint their respective expertises in a complementary synergism to reach the objectives proposed. Horus Pharma, a French pharmaceutical company, specialised on production, distribution and sales of pharmaceutical and biotech products for eye therapy and diagnostic; and Bioftalmik, a Spanish company specialised on biomarker discovery and development of medical devices for ophthalmology applications.This project is crucial for the economic growth and international expansion of both companies and constitutes the base for strategic development in the immediate future. Fields of science medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsnatural sciencesbiological sciencesbiochemistrybiomoleculesproteinsmedical and health sciencesclinical medicineophthalmology Programme(s) H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme H2020-EU.3.1.3. - Treating and managing disease Topic(s) PHC-12-2014-1 - Clinical research for the validation of biomarkers and/or diagnostic medical devices Call for proposal H2020-SMEInst-2014-2015 See other projects for this call Sub call H2020-SMEINST-1-2014 Funding Scheme SME-1 - SME instrument phase 1 Coordinator HORUS PHARMA SAS Net EU contribution € 50 000,00 Address 148 avenue georges guynemer 6700 Saint-laurent-du-var France See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Region Corse Corse Corse-du-Sud Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 21 429,00 Participants (1) Sort alphabetically Sort by Net EU contribution Expand all Collapse all BIOFTALMIK S.L. Spain Net EU contribution € 0,00 Address Parque tecnologico bizkaia edificio 800 2 planta 48160 Derio See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Region Noreste País Vasco Bizkaia Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 0,00
